Myomo Stock Price, News & Analysis

Myomo, Inc. (NYSE American: MYO) is a wearable medical robotics company in the surgical and medical instrument manufacturing industry. According to the company’s public disclosures, Myomo develops and markets advanced myoelectric orthoses designed to improve arm and hand function for individuals with neuromuscular disorders and upper-limb paralysis. The company’s business is centered on its proprietary MyoPro product line, which is described as a powered upper-limb orthosis that supports the arm and helps restore function to weakened or paralyzed arms.

Core products and technology

Myomo states that its MyoPro devices are designed for certain patients suffering from conditions such as CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, or other neuromuscular disease or injury. The company reports that MyoPro is registered with the U.S. Food and Drug Administration as a Class II medical device. In its descriptions, Myomo notes that MyoPro is the only marketed device in the U.S. that, by sensing a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks.

Myomo has also announced the MyoPro 2x, described as the latest evolution in its flagship MyoPro product line. The company characterizes MyoPro 2x as focusing on improvements in donning (putting on the device), fit and function, with the goal of enhancing user independence. According to Myomo, the product incorporates inputs from users and clinicians and insights from thousands of patients who have received a MyoPro.

Patients, clinical use and functional goals

Across its public communications, Myomo emphasizes that its devices are intended to help individuals perform daily activities such as eating, lifting or carrying objects and completing household tasks. The company reports that many users are able to return to work, live more independently and reduce their cost of care when using MyoPro devices. Clinical teams and Certified Prosthetists Orthotists (CPOs) play a role in evaluating candidates, fitting devices and supporting ongoing use.

Myomo describes a patient pipeline that includes medically qualified candidates who are in the process of obtaining a MyoPro. The company tracks authorizations and orders, revenue units, and insurance-related metrics such as Medicare Part B reimbursement, and it highlights the role of orthotics and prosthetics (O&P) providers as a distribution and care channel.

Business model and revenue channels

According to the company’s own descriptions, Myomo is a wearable medical robotics and myoelectric orthotics business. The company states that it provides MyoPro devices directly to patients and bills their insurance companies, and in some cases utilizes the clinical services of orthotics and prosthetics providers for which a fee is paid. Myomo also reports that it sells its products to O&P providers around the world and to the Veterans Health Administration (VA).

In recent communications, Myomo has highlighted several recurring revenue-related sources: U.S. and international O&P providers and a program called MyoConnect, which is described as a strategy to generate recurring patient referrals. Under MyoConnect, the company’s clinical team engages with therapists and physicians to expand a network of healthcare professionals who understand the benefits of MyoPro and can refer appropriate patients.

Operations, reimbursement and manufacturing

Myomo is headquartered in Burlington, Massachusetts, and reports that it has sales and clinical professionals across the U.S. and representatives internationally. The company’s disclosures indicate that it focuses on marketing and commercialization efforts, reimbursement from third-party payers (including Medicare Part B and private payers), and collaborations with O&P providers.

The company discusses manufacturing cost reduction projects that are intended to improve gross margin over time, as well as investments in its headquarters and manufacturing facility. Myomo also notes that it is subject to various risks and factors, including its ability to obtain sufficient reimbursement, dependence on external financing, scaling operations, maintaining strategic collaborations, protecting intellectual property, and gaining and maintaining regulatory approvals.

Capital structure and financing

Myomo is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-38109. The company has disclosed a Loan and Security Agreement with Avenue Capital-related entities that provides for term loans secured by a lien on the company’s assets, including intellectual property. The agreement includes financial covenants related to minimum cash balances, revenue performance and cash burn, as well as provisions for warrants to purchase shares of common stock and potential conversion of portions of the loan principal into equity.

In addition, Myomo has reported a salary-for-restricted stock units (RSUs) program for certain executives, under which a portion of base salary can be exchanged for RSUs subject to vesting conditions. These arrangements are documented in the company’s Form 8-K filings.

Regulatory status and risk considerations

Myomo’s public filings and press releases include detailed risk factor discussions and forward-looking statements. The company identifies factors that may affect its performance, such as reimbursement dynamics with Medicare and private insurers, supply chain considerations, marketing and commercialization effectiveness, clinical research outcomes, internal control over financial reporting, intellectual property protection, and competition in a highly competitive and evolving industry.

Investors and other stakeholders can review Myomo’s annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K for more detailed information about its financial condition, operating metrics, risk factors and material agreements. These SEC filings provide context on revenue composition, gross margin, operating expenses, cash position, debt arrangements and non-GAAP measures such as Adjusted EBITDA, as described by the company.

Stock information

Myomo’s common stock trades on the NYSE American exchange under the ticker symbol MYO. The company’s disclosures present it as a specialized participant in the wearable medical robotics and myoelectric orthotics space, focused on restoring upper-limb function for individuals with neurological and neuromuscular conditions through its MyoPro product line and related clinical and distribution channels.

Frequently asked questions (FAQ)

• What does Myomo, Inc. do?
  Myomo, Inc. is a wearable medical robotics company that develops and markets myoelectric orthoses intended to improve arm and hand function in individuals with neuromuscular disorders and upper-limb paralysis. Its business is centered on the MyoPro powered upper-limb orthosis product line.
• What is MyoPro?
  MyoPro is described by the company as a powered upper-limb orthosis designed to support the arm and help restore function to weakened or paralyzed arms of certain patients with conditions such as CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, or other neuromuscular disease or injury.
• How does MyoPro work according to the company?
  Myomo states that MyoPro is the only marketed device in the U.S. that senses a patient’s own EMG signals through non-invasive sensors on the arm and uses those signals to restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks.
• Who are typical candidates for MyoPro devices?
  Based on the company’s descriptions, candidates include individuals with upper-limb paralysis or weakness due to CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, or other neuromuscular diseases or injuries, who may benefit from powered assistance to perform daily activities.
• How does Myomo generate revenue?
  Myomo reports that it provides MyoPro devices directly to patients and bills their insurance companies, sometimes using the clinical services of orthotics and prosthetics providers for a fee. It also sells products to O&P providers around the world and to the Veterans Health Administration.
• What is the MyoPro 2x?
  The MyoPro 2x is described as the latest evolution of the MyoPro product line, with a focus on improving donning, fit and function to enhance user independence. Myomo reports that its design was informed by feedback from users and clinicians and by product performance data.
• Where is Myomo headquartered?
  Myomo states that it is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally.
• On which exchange is MYO stock listed?
  Myomo’s common stock is listed on the NYSE American exchange under the ticker symbol MYO.
• What are some key risks Myomo identifies in its filings?
  The company cites risks related to reimbursement from third-party payers, dependence on external financing, the ability to scale operations, marketing and commercialization efforts, internal controls, product development, regulatory approvals, intellectual property protection and competition.
• Where can investors find more detailed information on Myomo?
  Investors can review Myomo’s SEC filings, including Forms 10-K, 10-Q and 8-K, which the company references in its press releases as containing additional details on financial results, risk factors, material agreements and other regulatory disclosures.